908 related articles for article (PubMed ID: 19292800)
1. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
3. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
4. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
5. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
[TBL] [Abstract][Full Text] [Related]
7. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
8. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
Goldstein NS; Decker D; Severson D; Schell S; Vicini F; Margolis J; Dekhne NS
Cancer; 2007 Oct; 110(8):1687-96. PubMed ID: 17722109
[TBL] [Abstract][Full Text] [Related]
9. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
10. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
12. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK
Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
[TBL] [Abstract][Full Text] [Related]
13. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
14. An analysis of prognostic features in infiltrating lobular carcinoma of the breast.
Frost AR; Terahata S; Yeh IT; Siegel RS; Overmoyer B; Silverberg SG
Mod Pathol; 1995 Oct; 8(8):830-6. PubMed ID: 8552571
[TBL] [Abstract][Full Text] [Related]
15. A subset of breast invasive ductal carcinoma with distinctive cytomorphology, aggressive clinical behavior, and unique immunologic profiles.
Lu D; Masood S; Khalbuss WE; Bui M
Cancer; 2002 Oct; 96(5):294-300. PubMed ID: 12378597
[TBL] [Abstract][Full Text] [Related]
16. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
17. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
Sinn HP; Schmid H; Junkermann H; Huober J; Leppien G; Kaufmann M; Bastert G; Otto HF
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):552-8. PubMed ID: 8001751
[TBL] [Abstract][Full Text] [Related]
18. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
19. Biologic tumor markers, lymph node status, and decision about adjuvant chemotherapy for breast cancer.
Velanovich V
Am Surg; 1997 Apr; 63(4):330-3. PubMed ID: 9124752
[TBL] [Abstract][Full Text] [Related]
20. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
